New drug duo takes on tough pancreatic cancer

NCT ID NCT06773130

Ongoing Disease control Sponsor: West China Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial is testing whether two drugs, HRS-4642 and nimotuzumab, can safely shrink tumors in people with recurrent or metastatic pancreatic ductal adenocarcinoma. About 20 patients will receive the combination to find the best dose and see how well it works. The goal is to control the disease, not cure it.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HRS-4642 and nimotuzumab
What this could lead to: If successful, this combination could offer a new treatment option for people with advanced pancreatic cancer that has come back or spread.
What could go wrong: This is a very early, small trial (20 people) combining two drugs for the first time in this cancer. It may not work or could have serious side effects. Pancreatic cancer is notoriously hard to treat.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREATIC DUCTAL ADENOCARCINOMA (PDAC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pancreatic ductal adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)

Contacts and locations

Show contact details

Locations

West China Hospital, Sichuan University

Chengdu, Sichuan, 610041, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.